• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Cervarix / Protecting High-risk Girls Against HPV

Protecting High-risk Girls Against HPV

September 2, 2010 By Jonathan Leave a Comment

Today at Brown

Brown University
By Anne Coyle  |  May 5, 2010

The human papilloma virus is the most common sexually transmitted disease in the United States. A new Brown study may help immunize an especially vulnerable population: incarcerated adolescent girls.

Six million Americans are expected to become infected with the human papilloma virus (HPV) annually, and an estimated 50 percent of sexually active people will have HPV at some point in their lives.

Given these rates of infection and the availability of several FDA-approved vaccines for girls and women, a research team from Miriam Hospital and Brown University – Courtney E. Henderson, administrative director for the Center for Clinical and Translational Sciences; Josiah D. Rich, professor of medicine and community health; and Michelle A. Lally, director of the HIV Vaccine Clinical Trials Unit for Brown University/The Miriam Hospital – decided to study the vaccination rates of girls and young women in the juvenile justice system. Their study, which appears in the May issue of the Journal of Adolescent Health, is the first nationwide review of HPV vaccinations among this population.

Girls in juvenile justice facilities may be at particularly high risk for HPV and often do not receive consistent health care. The researchers recommend that all states make the HPV vaccine available to girls in the system, make the consent procedure easier, and increase HPV-vaccine education efforts.

TAB spoke with Courtney Henderson about the need for an improved prevention program.

___________________________________________

Why is this study significant?

This is the first known study of HPV vaccination practices among juvenile justice facilities in the United States, and one of the very few studies of vaccination practices in general among this population. We hope that our research will provide new insights into how to improve the health of this marginalized population.

Most states, including Rhode Island, administer the HPV vaccine to girls in juvenile justice facilities. Of the states that provide the vaccine, 69 percent allow the state or facility superintendent to provide consent for vaccination of the adolescents. Of the states that did not provide the vaccine, the most commonly cited barrier was a lack of education among adolescents regarding the vaccine and its benefits.

What is the risk of a young woman getting HPV?

HPV is the most common sexually transmitted infection in the United States and poses a health risk for all Americans who are sexually active. Certain strains of HPV are associated with genital warts and some cancers, particularly cervical cancer. The Food and Drug Administration licensed a preventive vaccine in 2006, and the Advisory Committee on Immunization Practices recommends universal vaccination for all females between the ages of 11 and 26 years.

Are young women in the juvenile justice system at greater risk?

Yes. These girls have an earlier onset of sexual activity and an increased number of sexual partners when compared to national averages of sexual activity among youth. In 2001, the American Academy of Pediatrics recommended that special attention be focused on the immunization status of incarcerated adolescents, as many of these youth lack a medical “home” in which to receive consistent health care. The juvenile justice setting provides a unique opportunity to administer the HPV vaccine to a population that may not otherwise seek healthcare services.

Why don’t we already vaccinate all incarcerated adolescent girls?
The good news is that 39 states offer the HPV vaccine in their juvenile justice facilities. However, only 15 of these states offer the HPV vaccine to all the girls entering those facilities. This includes both committed girls, who will be housed within the juvenile justice system for an extended period of time, and detained girls, who will only be in the system for a short period of time. The remaining states either offer the vaccine inconsistently to their detained population or do not offer it at all, primarily due to the brevity of the detainees’ stays.

Other barriers that we identified included a general lack of education among adolescents regarding HPV vaccination, parental consent requirements, a lack of adequate healthcare staff to administer the vaccine, adolescents’ fear of needles, and cost.

What do you anticipate the impact of your study will be?
We would hope to see a greater awareness about the benefits of the HPV vaccine and an increase in vaccination rates in this population. Girls in juvenile justice facilities will eventually become part of the general population again, so any opportunity we have to improve their health will ultimately lead to improvements in the overall health of our communities.

Source: Today at Brown

Related

Filed Under: Cervarix, Gardasil / Silgard Tagged With: cervarix, Cervical Cancer HPV, Gardasil/Silgard, HPV VACCINES, vaccinations, Vaccine Adverse Reactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil: We're all in this together

Gardasil: My Family Suffers with Me

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Doctors Denying Vaccine Risks: An American Tragedy

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in